Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Neuroendocrine Tumors 12Neoplasms 8Carcinoid Tumor 7Diarrhea 6Colorectal Neoplasms 6Carcinoma, Hepatocellular 6Breast Neoplasms 5Acromegaly 5Vipoma 4Stomach Neoplasms 4Somatostatinoma 4Rectal Neoplasms 4Insulinoma 4Glucagonoma 4Gastro-enteropancreatic neuroendocrine tumor 4Esophageal Neoplasms 4Carcinoma, Islet Cell 4Adenoma, Islet Cell 4Weight Loss 3Prostatic Neoplasms 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Intestinal Obstruction 3Gastrinoma 3Colonic Neoplasms 3Carcinoma 3Thymoma 2Pituitary Neoplasms 2Ovarian Neoplasms 2Meningioma 2

Interventions

Cyclophosphamide 153Dexamethasone 141Rituximab 85fludarabine 79Lenalidomide 72Cytarabine 70Bortezomib 64fludarabine phosphate 63Gemcitabine 62venetoclax 54Etoposide 53pomalidomide 52pembrolizumab 52Paclitaxel 48Cisplatin 48Carboplatin 48Peripheral Blood Stem Cell Transplantation 47Filgrastim 40Radiotherapy 39Busulfan 37Calcium Dobesilate 36Methotrexate 34Melphalan 34Bevacizumab 33carfilzomib 32Cyclosporine 32Azacitidine 32Mycophenolic Acid 30Vincristine 29Bendamustine Hydrochloride 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × Octreotide × Clear all
NCT06865677 2026-01-21

Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
2 enrolled 7 charts

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡